Tocilizumab for the Treatment of Refractory Behcet's Uveitis

Stopped The study was terminated based on its primary and secondary outcome measures in three consecutive patients.

Conditions

• Behcet Syndrome
• Uveitis

Interventions

• BIOLOGICAL: Tocilizumab (TCZ)

Sponsor

Wenjie Zheng